Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Strong sales in breast cancer lift Roche revenues

Strong sales in breast cancer lift Roche revenues New products Perjeta and Kadcyla lead growth. Rocketing sales of Roche's new breast cancer drugs Perjeta and Kadcyla suggest they will cushion any impact from biosimilar competition to Herceptin, which ... Last month, Roche reported new clinical data

Janssen, AZ and Roche at ESMO

Janssen, AZ and Roche at ESMO In addition to using ESMO to post data that suggests Perjeta (pertuzumab) should be the new standard in breast cancer, the company also presented positive results for its investigational MEK inhibitor

Roche's Perjeta should be 'new standard' in breast cancer

Roche's Perjeta should be 'new standard' in breast cancer Adding Roche's Perjeta to therapy with Herceptin and docetaxel has a dramatic impact on survival in patients with HER2-positive metastatic breast cancer, according to new trial data. ... With the latest CLEOPATRA data in hand the argument for the

Dive in: gaining leadership in a therapeutic area

Dive in: gaining leadership in a therapeutic area neu (4B5) Rabbit Monoclonal Primary Antibody assay marketed by its subsidiary Ventana - used to detect breast cancer patients eligible for Herceptin, Perjeta and Kadcyla.

Back to the future

Back to the future In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

[ Previous 5 results ] 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics